To explore the outcomes of young women who wanted pregnancy and had undergone assisted reproductive after treatment of their malignant tumors, and to study its impact on the safety of the off-springs of these women. Methods: The women with malignant tumors who had undergone in vitro fertilization/ intracytoplasmic sperm injection (IVF/ICSI) and embryo transfer (ET) were selected in study group from January 2015 to December 2020. The women in control group were matched using the propensity scoring method in a 1:3 ratio of the women in the study in accordance with the age, body mass index (BMI), and basic follicle stimulating hormone (FSH), the number of antral follicles (AFC), and the egg retrieval time. The pregnancy outcomes and the off-springs safety of the women were compared between the two groups. Results: The days of gonadotropin (Gn) used (11.1±3.0d) of the women in the study group was significantly shorter than that (11.5±2.4d) of the women in the control group (P=0.014). The level of luteinizing hormone (LH) of the women in the study group (5.9±2.7 U) on the hormone of chorionic gonadotropin (hCG) injection day was significantly higher than that (3.2±2.6U) of the women in the control group (P=0.048). The number of eggs retrieved (11.5±9.47) of the women in the study group was significantly less than that (11.8±6.7) of the women in the control group (P=0.042). The fertilization rate (76.5%) of the women in the study group was significantly lower than that (58.5%) of the women in the control group (P=0.006). The rate of quality of embryo (58.5%) of the women in the study group was significantly higher than that (49.7%) of the women in the control group (P=0.041). There were no significant differences in the values of other indicators of the women between the two groups (P>0.05). The number of embryos in the first time of transferred (1.7±0.3) of the women in the study group was significantly higher than that (1.4±0.5) of the women in the control group (P=0.049), but there were no significant differences in the source and type of the embryos transferred in the first time, the clinical pregnancy rate, and the implantation rate of the women between the two groups (P>0.05). The gestational days (203.9±149.5d) of the women in the study group was significantly longer than that (123.4±62.4d) of the women in the control group (P=0.000). The cycles of oocyte retrieval per live birth (2.7) of the women in the study group was significantly more than that (1.9) of the women in the control group (P=0.030). The cycles of transplantation (2.9) of the women in the study group was significantly more than that (2.2) of the women in the control group (P=0.004). The number of embryos (4.6) of the women in the study group was significantly more than that (3.3) of the women in the control group (P=0.006). There were no significant differences in the cumulative pregnancy rate, the cumulative live birth rate, and the number of high-quality embryos per live birth of the women between the two groups (P>0.05). There were no significant differences in the delivery mode, the gestational weeks at delivery, the fetal birth weight, and the incidence of pregnancy complications of the women between the two groups (P>0.05). Conclusion: The assisted reproductive technology can met the reproductive needs of the young women after malignant tumor surgery, and which is safety.